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Summary Angelman syndrome is a neurogenetic disorder caused by lack of UBE3A
gene expression from the maternally inherited chromosome 15 due to various 15q11-
q13 abnormalities. In addition to severe developmental delay, virtual absence of
speech, motor impairment, a behavioural phenotype that includes happy demeanour,
and distinctive rhythmic electroencephalographic features, over 90% of patients have
epilepsy. Many different seizure types may occur, atypical absences and myoclonic
seizures being particularly prevalent. Non-convulsive status epilepticus is common,
sometimes in the context of the epileptic syndrome referred to as myoclonic status in
non-progressiveencephalopathies. Epilepsypredominates inchildhood,butmaypersist
or reappear inadulthood.Management is difficult in a proportion ofpatients. Itmightbe
improved by better understanding of pathophysiology. Current hypotheses involve
abnormal inhibitory transmissiondueto impairedregulationofGABAAreceptors related
to functional absence of UBE3A and abnormal hippocampal CaMKII activity.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Contents
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212 K. Pelc et al.Interest in monogenic disorders with epilepsy has
provided significant insights into the pathophysiol-
ogy of epilepsy. Among these disorders, Angelman
syndrome has attracted particular attention
because of its complex genetics. Angelman
syndrome is characterised by developmental delay,
absence of speech, motor impairment, epilepsy and
a peculiar behavioural phenotype with apparent
happy demeanour. It is caused by the lack of expres-
sion of the UBE3A gene, which can result from
various abnormalities of chromosome 15q11-q13.
Similar abnormalities of chromosome 15q11-q13
result either in Angelman syndrome if they concern
the chromosome inherited from the mother, or in
Prader-Willi syndrome (a clinically distinct condition
with hypotonia, learning difficulties, obesity and
hypogonadism), if they concern the chromosome
of paternal origin. The factor determining the phe-
notypic outcome is the parental origin of the chro-
mosome 15 defect, illustrating the phenomenon of
genomic imprinting. In about 70% of patients, Angel-
man syndrome is due to a de novo 15q11-q13 dele-
tion on the chromosome inherited from themother.1
This deletion cannot be identified with routine
chromosome studies but it can be detected with
fluorescence in situ hybridisation (FISH) using appro-
priate probes. Approximately 2—3% of patients have
inherited both copies of chromosome 15 from the
father and none from the mother, i.e. paternal
uniparental disomy.2 As a result, no functional copy
of the UBE3A gene is inherited from the mother. In
contrast to patients with a deletion, those with
uniparental disomy have a statistically less severe
phenotype.3 They have a low incidence of micro-
cephaly, less severe seizures and have more words,
although speech is extremely limited and not used
as a main communication tool. Another 3—5% of
patients have an imprinting defect resulting in a
lack of the typical maternal pattern of DNA methy-
lation.4 Statistically, the phenotype of patients with
an imprinting defect is indistinguishable form that
of patients with uniparental disomy.3 There is a
mutation in the maternal UBE3A gene5,6 in another
5—10% of patients. Most of them appear to be
private mutations, with a high occurrence rate of
de novo mutations. Finally, in up to 10% of typical
cases, no cytogenetic or molecular abnormality can
currently be found.
Overall, seizures occur in about 90% of patients
with Angelman syndrome. They are the most fre-
quent cause of hospital admission.7 Unprovoked and
provoked seizures may coexist. As mentioned
above, epilepsy is often more severe in patients
who have a chromosome 15q11-q13 deletion
(including genes coding for GABAA receptor subu-
nits) than in those in other molecular classes.8,9 Thisis consistent with generally milder neurobeha-
vioural features in patients without a deletion.3
Nevertheless, seizures tend to have a similar pat-
tern whatever the molecular class, with occurrence
in clusters alternating with seizure-free periods.
The clusters occur apparently spontaneously or they
may be precipitated by factors such as infection,
excitement, physical effort, intense fatigue, etc.Natural history of the seizure disorder
Onset of seizures is often before 3 years of age,
mostly between 1 and 3 years.10—13 Whereas epi-
lepsy is often a prominent clinical problem in child-
hood, seizure onset occurs during infancy in a
minority of patients. Less than 25% develop seizures
before 12 months of age11; 30% before 24 months.12
If seizures do occur in infants, they tend to do so in a
febrile context. In a high proportion of patients, the
onset of epilepsy precedes the diagnosis of Angel-
man syndrome.14 Seizure types may evolve with
age.15,16 As in other developmental conditions with
epilepsy, the seizure disorder often improves in late
childhood. Sustained seizure-freedom following epi-
lepsy in childhood has been found in four of five
patients with a 15q11-q13 deletion followed up
longitudinally until the age of 30 years or more.16
Other studies, however, have shown that epilepsy
can persist or reappear in adulthood.7,17 For exam-
ple, seizures were found to be the most prevalent
clinical problem in a group of adolescents and
adults, occurring in 11 of 28 surveyed patients (aged
16—40 years).18 Following a relatively quiescent
phase in the teenage years, eight of these patients
had an increase in seizures, which became difficult
to control during their mid-twenties. Laan et al.19
found that 23 of 28 the adults they studied (aged
20—53 years) had seizures.Seizure types
Many different types of seizures have been
reported, both generalised and focal. They include
epileptic spasms, myoclonic absences, myoclonic,
atonic, tonic and tonic—clonic seizures.8,15,20—24
Atypical absence and myoclonic seizures have been
particularly emphasised. In contrast, epileptic
spasms are uncommon. Multiple seizure types occur
in about half of the patients with a 15q11-q13
deletion.14
Patterns of seizures, including type, age of onset,
other clinical features and electroencephalographic
features of patients with Angelman syndrome may
show some resemblance with defined epileptic syn-
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terise their epilepsy correctly given implications
for both management and prognosis. Although epi-
leptic spasms are the typical seizure type of West
syndrome or infantile spasms (in association with
hypsarrhythmic electrencephalogram and ‘develop-
mental arrest’), this epileptic syndrome has rarely
been documented convincingly in Angelman syn-
drome. In the vast majority of cases, the electren-
cephalographic patterns seen in Angelman
syndrome can be differentiated easily from hypsar-
rhythmia.25 The most commonly identified of these
typical patterns consists of runs of rhythmic 2—3/s
activity of high amplitude often exceeding 300 mV
seen mainly over the frontal regions,21,26—29 i.e.
Pattern I in Dan and Boyd’s classification.25 Studying
this electroencephalographic pattern, Valente
et al.28 noted that it may rarely present in the form
of a ‘hypsarrhythmic-like’ variant consisting of runs
of high amplitude asynchronous delta activity asso-
ciated with multifocal spikes or sharp waves of
moderate amplitude. These authors emphasised
the differences between this feature and hypsar-
rhythmia, e.g. fragmentation of hypsarrhythmia
during sleep. Nevertheless, although Bower and
Jeavons had differentiated their electroencephalo-
graphic findings in early reported patients with
Angelman syndrome from hypsarrhythmia,30 some
authors have inappropriately referred to the rhyth-
mic electroencephalographic patterns seen in
Angelman syndrome, particularly Pattern I, as ‘hyp-
sarrhythmia’. This is misleading, as it may result in
wrong diagnosis and inadequate treatment.
Similarly, although tonic seizures and complex
absences can occur in Angelman syndrome, confu-
sion with Lennox-Gastaut syndrome can be avoided
without much difficulty in many cases. Confusion
with the electroencephalographic features of Len-
nox-Gastaut syndrome has also arisen in some
reports, although the runs of slow spike—wave com-
plexes seen in Angelman syndrome are usually
rhythmic and signal non-convulsive status epilepti-
cus (which has no specific features and is indeed
indistinguishable from that seen in Lennox-Gas-
taut). Nevertheless, this label has been misused
in a number of reports.
In contrast, another epileptic syndrome, referred
to as myoclonic status in non-progressive encepha-
lopathies, has been appropriately recognised in a
number of patients with Angelman syndrome.31 This
syndrome is characterised by recurrent episodes of
myoclonic status in patients who have pre-existing
non-progressive neurological deficits including
severe intellectual disability, axial hypotonia and
ataxia.32 It also occurs in Wolff-Hirschhorn syn-
drome (4p-syndrome), neonatal encephalopathyand metabolic disorders such as non-ketotic hyper-
glycinaemia.
Another condition, which is not an epileptic syn-
drome stricto sensu in the absence of seizures, is
electric status epilepticus during sleep, also known
as continuous spike—wave discharges during sleep.
The electroencephalographic features consists of
generalised slow (usually around 2/s) spike—wave
complexes, sometimes with a frontal emphasis,
occupying more than 85% of slow-wave sleep, while
this activity is exceedingly rare in rapid eye move-
ment sleep. When the triad of electroencephalo-
graphic continuous spike—wave discharges during
sleep, seizures (all types can occur except for tonic
seizures) and impairment of neuropsychological and
motor (e.g. ataxia) function is present, the condi-
tion can be regarded as an epileptic syndrome
termed ‘epilepsy with continuous spike—wave dis-
charges during sleep’. This syndrome has rarely
been documented in Angelman syndrome.33 The
lack of clinical alteration concomitant to the elec-
trographic epileptiform activity excludes it from the
context of non-convulsive status epilepticus.34
Both convulsive and non-convulsive status epi-
lepticus may occur. Compared to other conditions
with epilepsy, the latter is relatively common,
including in cases that are not due to 15q11-q13
deletion.15,16,20,21,27,35 Although non-convulsive
status epilepticus appears to be more common dur-
ing childhood, it can occur in infancy36 and adult-
hood.37 Electroencephalogram shows continuous
epileptic discharges which are distinct from the
typical rhythmic electroencephalographic features
of Angelman syndrome.25 The distinction between
generalised and complex partial non-convulsive sta-
tus epilepticus is often difficult to make. The term
‘dialeptic status epilepticus’, which refers to sei-
zure phenomenology with alteration of conscious-
ness as main ictal feature without any reference to
the origin, might appear more appropriate in this
context.34 Frequent or prolonged episodes of dia-
leptic status epilepticus may contribute to a poor
cognitive outcome, as suggested in other conditions
with epilepsy.38
In some cases, prolonged disabling tremor has
been ascribed to cortical myoclonus39 or myoclonic
status.36 Such disabling resting tremor may appear
in day-long clusters, particularly in adolescents or
adults.18,40 When severe, it may result in loss of
ability to eat or walk independently during epi-
sodes. The aetiology of this tremor remains unclear.
It seems to be non-epileptic in a number of cases. In
one report of two adult patients, associated cog-
wheel-type rigidity and bradykinesia suggested Par-
kinsonism and tremor improved dramatically on
levodopa.41 In another young adult, episodes of
214 K. Pelc et al.generalised shaking predominating in the upper
extremities were correlated with 4—10/s electro-
myographic bursts but no ictal electroencephalo-
graphic changes.42 The electromyographic features
were similar to the postural bursting activity
described in children with Angelman syndrome,43
although the latter was not associated with actual
tremor. The muscle activity associated with the
movements was so intense that it induced
hyperthermia and rhabdomyolysis. The movements
were effectively controlled by reserpine in associa-
tion with topiramate. This prominent, quasi-clonic
activity may be difficult to distinguish from myoclo-
nus. In a few other cases, fast-bursting myoclonus
has been correlated with electroencephalographic
activity of similar frequency or at subharmonics,
suggesting cortical myoclonus36,39 similar to findings
in Rett syndrome.44,45 Guerrini et al.39 reported
response to piracetam. We did not find any response
to either piracetam or levetiracetam in four of our
patients.
Finally, it must be noted that absence of electro-
encephalographic discharges correlated with bouts
of laughter suggests that they do not correspond to
gelastic seizures. Similarly, Sugimoto et al.35 found
no electroencephalographic changes during head
drops. Other possibly challenging spells include
stereotyped movements, tremors, staring episodes,
eye rolling, motor/behavioural manifestations of
gastro-oesophageal reflux (Sandifer syndrome) and
self-gratification episodes (‘masturbation’).Pathophysiology
Although the seizure disorder has been one of the
most studied aspects of Angelman syndrome, the
underlying pathophysiology is still a matter of spec-
ulation. Like many other features of Angelman syn-
drome, it has been hypothesised to be related to
dysfunction of the GABAA receptor complex, primar-
ily because the commonly deleted region of chro-
mosome 15q11-q13 contains a cluster of genes for
three of its subunits (a5, b3 and g3). Deficits in this
receptor have been related to neurodevelopmental
impairment and seizure disorder.46—48 The GABAA
receptor is associated with a gated chloride chan-
nel. In the mature brain, it plays a major role in
inhibitory neurotransmission. It is constituted by a
heteropentameric arrangement of individual subu-
nits from seven families (a, b, g, d, e, s and p). The
subunit composition of the heteropentameric com-
plex shows marked developmental changes. It may
affect the receptor properties, including kinetic
characteristics and the effects of allosteric modu-
lators (e.g. zinc, neurosteroids and benzodiaze-pines). Subunits a, b and g exist in multiple
isoforms. As a result, a great number of different
isoforms of GABAA receptor are possible. The
GABRB3, GABRG3 and GABRA5 genes, which code
for three subunits of the GABAA receptor (a5, b3 and
g3, respectively) are clustered in the 15q11-q13
region. These genes are expressed in several regions
of the adult brain and are even more abundant in
many regions of the embryonic and neonatal
brain.49 All known GABAA receptor subtypes contain
a b subunit and b3 is the only one present early in
life.49 Absence of a copy of the GABRB3, GABRG3
and GABRA5 genes has tentatively been related to
abnormalities in GABAergic neurotransmission.46
Knockout mice for Gabrb3, Gabrg3 and Gabra550
or for Gabrb3 alone51 have been proposed as animal
models for Angelman syndrome. The most relevant
of these models appears to be that produced by
disruption of the b3 subunit gene in mice, leading to
epilepsy and other abnormalities that show simila-
rities to Angelman syndrome.51 However, GABRB3
disruption does not account for all features of Angel-
man syndrome. For example, patients with 15q11-
q13 cytogenetic alterations, such as deletions on the
paternally derived chromosome (Prader-Willi syn-
drome), pericentromeric inversions and duplica-
tions (inv-dup(15) syndrome) or other types of
duplications (in some cases of autism), have distinct
clinical phenotypes. Furthermore, about 30% of
patients with Angelman syndrome do not have a
deletion involving the GABRB3 gene, i.e. patients
with imprinting defect, uniparental disomy, UBE3A
mutation or no detectable 15q11-q13 abnormality.
Although there is no evidence of imprinting of the
GABRB3 gene in humans, a recent study suggested
that there might be some (subtle) influence of
parent of origin and of gender in whole brain b3
subunit levels in Gabrb3-deficient heterozygous
mice.52
In contrast, all patients with a molecular diag-
nosis of Angelman syndrome have a functional
absence of the maternally inherited UBE3A gene.
The gene product (UBE3A) acts as an E3 ubiquitin—
protein ligase along the ubiquitin pathway.53 The
best-characterised function of ubiquitination is to
mark target proteins for specific proteolysis by pro-
teasomes. Ubiquitin-mediated proteolysis may be
important in a number of neuronal processes,
including synpatogenesis and mechanisms of long-
term memory. Ubiquitination pathways have been
implicated in the pathophysiology of other neuro-
logical disorders than Angelman syndrome.54 For
example, early-onset autosomal recessive Parkinson
disease is due to abnormalities of the gene coding
for parkin, another E3 ubiquitin—protein ligase.55 In
addition, the ubiquitin pathway may also be
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postsynaptic receptors.56 It has been suggested that
functional absence of UBE3A would impair the reg-
ulation of GABAA receptors.
25,57 In this hypothesis,
altered regulation of b3 subunit-containing GABAA
receptors would lead to ‘compensation’ involving
isoforms of the GABAA receptor which do not contain
the b3 subunit.58 This might result in changes in the
receptors’ kinetics and desensitisation properties.59
Although these changes are expected to be subtle,
they may have extensive effects during brain
maturation as well as through the patient’s life.
Alternative or additional mechanisms of epilep-
togenesis possibly involve abnormal intracellular
calcium signalling, including abnormal Ca++/calmo-
dulin-dependent protein kinase II.60,61 Other, less
specific mechanisms are likely to play major roles in
epilepsy seen in Angelman syndrome and other
neurodevelopmental disorders, particularly those
with intellectual disability, whether or not due to
chromosome abnormalities. However, very little is
currently known about these mechanisms. Synaptic
mechanisms are mostly understood as affecting
some ‘balance’ between excitatory and inhibitory
influences. As mentioned above, the focus in Angel-
man syndrome has been directed on GABAA-
mediated inhibition. Synaptic modulation and plas-
ticity probably deserve more attention. In addition,
the potential role of non-synaptic mechanisms of
neuronal synchrony, such as gap junctions, has not
been investigated (except in the cerebellum62).Management
Seizures may be difficult to control with pharmaco-
logical treatment, particularly in childhood. How-
ever, in a study of 68 patients, 91% of whom had
epilepsy, 43% were controlled by the initial thera-
peutic option.63 Surveys of antiepileptic drugs used
in patients with Angelman syndrome have suggested
that sodium valproate is the most commonly used.64
The use of clonazepam has also been reported in a
number of cases. These drugs have been recom-
mended on the basis of early reports of retrospec-
tive, open studies of limited patient series. The
effectiveness of other benzodiazepines, such as
nitrazepam and clobazam, seems to be similar to
that of clonazepam in patients with Angelman syn-
drome.9 However, in the majority of patients, the
use of benzodiazepines does not appear to be jus-
tified as a first-line treatment. Phenobarbitone can
be both effective and well tolerated in infants.
Because of sedative or cognitive side effects, it is
less used in children and older patients. However,
Clayton-Smith and Laan65 have suggested that itmay be a good option in adults. Levetiracetam,
topiramate, ethosuximide and lamotrigine have
been successfully used in many cases, but there is
a lack of controlled studies. It is noteworthy that
although lamotrigine drug has no direct effect on
GABAA receptors,
66 it might promote GABRB3 gene
expression in hippocampal cells.67
Some antiepileptic drugs may be paradoxically
detrimental through increase in the risk of seizures,
facilitation of the development of other seizure
types or precipitation of non-convulsive status epi-
lepticus. These drugs include carbamazepine,8,14,19
oxcarbazepine,14 vigabatrin,9,14,68 tiagabine and
probably gabapentin. However, this observation
does not imply absolute contraindication of these
drugs, whichmay prove useful in some patients. This
aggravation due to antiepileptic drugs is not specific
to Angelman syndrome, where it appears to be more
marginal than in some epileptic syndrome, notably
idiopathic generalised epilepsies.
Response of non-convulsive status epilepticus to
treatment is variable and management may be
difficult. Oral benzodiazepines, corticosteroids
and ketamine69 may be early options, but there
has been a marked lack of well-designed studies.
Morbidity associated with aggressive treatment may
outweigh the risk of therapeutic abstention. In con-
trast, convulsive status epilepticus requires early
effective treatment according to common treat-
ment protocols.
Non-pharmacological management is rarely con-
sidered, despite the relatively high prevalence of
drug resistance. Ketogenic diet was effective in four
patients with refractory epilepsy in Valente
et al.’s14 series.Conclusion
Patients with Angelman syndrome have an increased
risk of epilepsy. Compared to many other neurode-
velopmental disorders, the risk seems remarkably
high. In particular, early-childhood onset of refrac-
tory epilepsy with atypical absences and myoclonic
seizures with predisposition to developing non-con-
vulsive status epilepticus is a common presentation.
This may be due to propensity to hypersynchronous
neuronal activity, which might be related to abnor-
mal GABA-mediated transmission due to lack of
UBE3A expression, or other factors. In recent years,
there has been increasing awareness of the possibi-
lity of seizure disorder in adult patients. However,
epilepsy may be difficult to diagnose. On the one
hand, non-epileptic stereotyped or paroxysmal
events (including motor or behavioural manifesta-
tions) may lead to overdiagnosis. On the other hand,
216 K. Pelc et al.the epileptic nature of relatively subtle manifesta-
tions such as absences, myoclonias or non-convul-
sive status epilepticus may be under-recognised in
the context of behavioural and motor features. The
neurocognitive effects of seizures are difficult to
evaluate. There is a major need for evidence on
which to base rational treatment.References
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